MBL2: A Potential Drug Target and Biomarker for Cancer (G4153)

Target Name: MBL2

NCBI ID: G4153

MBL2: A Potential Drug Target and Biomarker for Cancer

MBL2 (Mucinases and proteases, 2) is a gene that encodes a protein known as MBL2. MBL2 is a member of the Mucinases and proteases family and is located on chromosome 17. It is a 21-kDa protein that is expressed in a variety of tissues, including the skin, heart, liver, and pancreas.

MBL2 has been identified as a potential drug target and is being studied for its potential therapeutic uses. One of the main reasons for studying MBL2 is its role in cancer progression. MBL2 has been shown to be involved in the development and progression of several types of cancer, including breast, ovarian, and colorectal cancer.

In addition to its role in cancer, MBL2 has also been shown to be involved in a variety of other physiological processes in the body. For example, it is involved in the regulation of cell adhesion, migration, and invasion, and it has been shown to play a role in the development and maintenance of the blood-brain barrier.

MBL2 is also of interest as a potential biomarker for several types of cancer. For example, MBL2 has been shown to be expressed in the primary tumors of several types of cancer, including breast, ovarian, and colorectal cancer. Additionally, MBL2 has been shown to be involved in the development and progression of cancer stem cells, which are a type of cell that can give rise to fully developed tumors.

In conclusion, MBL2 is a protein that is of interest in the development and progression of cancer, as well as the regulation of other physiological processes in the body. As a result, it is a potential drug target and biomarker for several types of cancer. Further research is needed to fully understand the role of MBL2 in these processes and to develop effective therapies for the treatment of cancer.

Protein Name: Mannose Binding Lectin 2

Functions: Calcium-dependent lectin involved in innate immune defense (PubMed:35102342). Binds mannose, fucose and N-acetylglucosamine on different microorganisms and activates the lectin complement pathway. Binds to late apoptotic cells, as well as to apoptotic blebs and to necrotic cells, but not to early apoptotic cells, facilitating their uptake by macrophages. May bind DNA. Upon SARS coronavirus-2/SARS-CoV-2 infection, activates the complement lectin pathway which leads to the inhibition SARS-CoV-2 infection and a reduction of the induced inflammatory response (PubMed:35102342)

More Common Targets